Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
24-26 February, 2026
Global ChemShowGlobal ChemShow
Not Confirmed
Not Confirmed
19-20 December, 2025
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 February, 2026
Global ChemShowGlobal ChemShow
Industry Trade Show
Not Confirmed
19-20 December, 2025
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Digital content

30 Aug 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/castle-creek-biosciences-announces-publication-of-preclinical-study-for-potential-in-vivo-gene-therapy-in-nature-communications-301614779.html

20 May 2022
// Kyle LaHucik ENDPTS
https://endpts.com/scoop-after-pulling-ipo-ambitions-last-december-jeff-aronins-castle-creek-turns-to-private-backers/

30 Dec 2021
// John Carroll ENDPTS
https://endpts.com/a-jeff-aronin-startup-quietly-yanks-its-ipo-as-the-biotech-market-ends-year-on-a-whimper/

21 Oct 2021
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/castle-creek-biosciences-awarded-fda-orphan-products-development-grant-to-support-defi-rdeb-a-pivotal-phase-3-study-of-fcx-007-investigational-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa-301405636.html

19 Jul 2021
// Kyle LaHucik FIERCEBIOTECH
https://www.fiercebiotech.com/biotech/castle-creek-eliem-and-adagio-three-biotechs-filed-for-ipos-friday-continued-public-frenzy

28 Oct 2020
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/castle-creek-biosciences-announces-first-patient-dosed-in-defi-rdeb-phase-3-clinical-trial-of-debcoemagene-autoficel-d-fi-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa-301161536.html
ABOUT THIS PAGE